Power to the Tregs in transplantation tolerance in LATAM: From the basics to the bedside
Karina Pino-Lagos & Gloria Soldevila — Seminars in Immunology, 2026
This review examines the central role of regulatory T cells (Tregs) in establishing and maintaining immune tolerance, with a particular focus on their potential to prevent transplant rejection. Tregs comprise several subsets—including thymic Tregs (tTregs), induced Tregs (iTregs), and Tr1 cells—that suppress excessive immune responses through multiple mechanisms, including inhibitory cytokines, cell-to-cell interactions, metabolic regulation, extracellular vesicles, and modulation of antigen-presenting cells.
The paper highlights research from Latin America, particularly Mexico, Chile, Brazil, Argentina, Colombia, and Cuba, showing how regional scientists have contributed to understanding Treg biology and transplantation tolerance. The work of Pino-Lagos and colleagues in Chile has helped define the roles of Neuropilin-1 (Nrp1), IL-33, extracellular vesicles, and metabolic pathways in Treg-mediated graft acceptance. Across the region, studies have investigated Tregs in kidney, skin, intestinal, hematopoietic and other transplantation settings.
Importantly, the review connects this basic research with the emerging use of Tregs as cellular therapies. Clinical and preclinical studies suggest that expanding or engineering regulatory cells—including antigen-specific Tregs and CAR-Tregs—could promote graft-specific tolerance and potentially reduce dependence on lifelong systemic immunosuppression. However, translating these approaches into routine clinical practice requires reliable cell isolation and expansion, functional stability, appropriate homing to the graft, GMP-compliant manufacturing and regulatory frameworks.
For Latin America, these scientific challenges are compounded by limited funding, unequal research infrastructure, restricted access to advanced technologies, insufficient GMP facilities and difficulties in maintaining long-term patient monitoring. The authors emphasize greater investment, regional and international collaboration, technological modernization, stronger links between scientists and clinicians, and the development of precision-medicine approaches as important steps toward bringing Treg-based therapies from the laboratory to transplant patients.
Overall, the paper positions Tregs as a promising bridge between fundamental immunology and the development of more precise approaches to transplantation tolerance, while highlighting Latin America’s growing scientific contribution and the barriers that still need to be overcome for clinical translation.